Literature DB >> 16634110

Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor.

Béla Dénes1, Daila S Gridley, Nadja Fodor, Zsuzsanna Takátsy, Tatyana M Timiryasova, István Fodor.   

Abstract

BACKGROUND: Interferons (IFNs) play an important role in host antiviral responses, but viruses, including vaccinia viruses (VV), employ mechanisms to disrupt IFN activities, and these viral mechanisms are often associated with their virulence. Here, we explore an attenuation strategy with a vaccine strain of VV lacking a virus-encoded IFN-gamma receptor homolog (viroceptor).
METHODS: To facilitate the monitoring of virus properties, first we constructed a Lister vaccine strain derivative VV-RG expressing optical reporters. Further, we constructed a VV-RG derivative, VV-RG8, which lacks the IFN-gammaR viroceptor (B8R gene product). Replication, immunological and pathogenic properties of the constructed strains were compared.
RESULTS: Viruses did not show significant differences in humoral and cellular immune responses of immune-competent mice. Replication of constructed viruses was efficient both in vitro and in vivo, but showed marked difference in kinetics of propagation. In cultured CV-1 epithelial cells, the VV-RG8 strain retained the propagation potential of the parental virus, while, in the C6 glial cells, significant delay was observed in the kinetics of the VV-RG8 replication cycle compared to VV-RG. The pathogenesis of the viruses was tested by survival assay and biodistribution in nude mice. High dose inoculation of nude mice with VV-RG8 caused less pronounced virus dissemination, improved weight gain, and increased survival rate, as compared with the VV-RG strain.
CONCLUSIONS: The replication-competent virus VV-RG8 carrying a mutation at the B8R gene is less pathogenic for mice than the parental vaccine virus. We anticipate that step-wise inactivation of VV vaccine genes involved in evasion of host immune response may provide an alternative approach for generation of hyper-attenuated replication-competent vaccines. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16634110     DOI: 10.1002/jgm.907

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  6 in total

1.  N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.

Authors:  Meike S Gratz; Yasemin Suezer; Melanie Kremer; Asisa Volz; Monir Majzoub; Kay-Martin Hanschmann; Ulrich Kalinke; Astrid Schwantes; Gerd Sutter
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 2.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

3.  Autoantigens plus interleukin-10 suppress diabetes autoimmunity.

Authors:  Béla Dénes; István Fodor; William H R Langridge
Journal:  Diabetes Technol Ther       Date:  2010-08       Impact factor: 6.118

4.  Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Jose Luis Nájera; Carlos Oscar S Sorzano; Victoria Jiménez; Rubén González-Sanz; Mariano Esteban
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

5.  Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer.

Authors:  J R Tysome; A Briat; G Alusi; F Cao; D Gao; J Yu; P Wang; S Yang; Z Dong; S Wang; L Deng; J Francis; T Timiryasova; I Fodor; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2009-07-09       Impact factor: 5.250

6.  Attenuation of Vaccinia Virus.

Authors:  S N Yakubitskiy; I V Kolosova; R A Maksyutov; S N Shchelkunov
Journal:  Acta Naturae       Date:  2015 Oct-Dec       Impact factor: 1.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.